CD8A and cancer: In particular, besides enhancing the CD8 T cell-mediated response, HMAs are involved in the depletion of immune suppressor cells, such as regulatory T cells (Tregs) and myeloid-derived suppressive cells (MDSCs), and are currently evaluated in several clinical trials as immune adjuvants for sensitizing cancer patients to checkpoint inhibitor immunotherapy.12